1. Home
  2. MITT vs TLSI Comparison

MITT vs TLSI Comparison

Compare MITT & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AG Mortgage Investment Trust Inc.

MITT

AG Mortgage Investment Trust Inc.

HOLD

Current Price

$3.92

Market Cap

175.6M

Sector

Real Estate

ML Signal

HOLD

Logo TriSalus Life Sciences Inc.

TLSI

TriSalus Life Sciences Inc.

N/A

Current Price

$2.30

Market Cap

151.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MITT
TLSI
Founded
2011
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medical Specialities
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
175.6M
151.2M
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
MITT
TLSI
Price
$3.92
$2.30
Analyst Decision
Buy
Strong Buy
Analyst Count
6
4
Target Price
★ $8.33
$7.80
AVG Volume (30 Days)
★ 486.6K
301.2K
Earning Date
11-04-2026
11-10-2026
Dividend Yield
★ 24.74%
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $45,151,000.00
Revenue This Year
N/A
$3.46
Revenue Next Year
$10.23
$19.48
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 53.41
52 Week Low
$3.77
$2.17
52 Week High
$9.27
$7.95

Technical Indicators

Market Signals
Indicator
MITT
TLSI
Relative Strength Index (RSI) 20.56 32.26
Support Level N/A $2.20
Resistance Level $8.15 $4.59
Average True Range (ATR) 0.28 0.37
MACD -0.07 -0.06
Stochastic Oscillator 5.12 9.26

Price Performance

Historical Comparison
MITT
TLSI

About MITT AG Mortgage Investment Trust Inc.

TPG Mortgage Investment Trust Inc is a real estate investment trust (REIT). It focuses on investing in a diversified risk-adjusted portfolio of residential mortgage-related assets in the U.S. mortgage market. Its objective is to provide attractive risk-adjusted returns to its stockholders over the long term through dividends and capital appreciation. The company focuses on its investment activities on acquiring and securitizing newly-originated residential mortgage loans within the non-agency segment of the housing market.

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

Share on Social Networks: